Medical Oncology

, Volume 27, Supplement 1, pp 62–66

Future directions in immunomodulatory therapy

Original Paper

DOI: 10.1007/s12032-009-9376-8

Cite this article as:
Lonial, S. Med Oncol (2010) 27(Suppl 1): 62. doi:10.1007/s12032-009-9376-8
  • 100 Downloads

Abstract

The role of immunomodulatory-based therapy with thalidomide or lenalidomide is clearly established in the management of patients with myeloma in all phases of their disease. Recent preclinical and clinical works have demonstrated that in addition to combination therapy with dexamethasone, there is significant activity when combined with the proteasome inhibitor bortezomib. More recent clinical studies have also demonstrated significant activity when combined with akt inhibitors, HDAC inhibitors, and even monoclonal antibodies. Further clinical development of immunomodulatory agents should continue to be based on preclinical rationale, which has resulted in a number of promising and clinically active combinations.

Keywords

Multiple myeloma Immunomodulatory therapy combination 

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Emory University School of MedicineAtlantaUSA

Personalised recommendations